Pharmgen Inosiflex Syrup (Inosiflex)

Adult dose

Adults: Administer 3~4 g daily as inosiplex (60~80 mL of this drug) orally in divided doses of 500 mg~1g (10~20 mL) every 4~6 hours.

Child dose

Pediatric patients: Administer 50~100 mg per kg of body weight per day orally in 6 divided doses.

This medication should not be used in patients who have had allergic reactions to this medication or its ingredients. Use with caution in patients with gout or high blood uric acid levels, as this medication may elevate uric acid levels and worsen symptoms. Patients with urinary stones or kidney stones should also be cautious, as this medication may increase uric acid levels and worsen stone symptoms. Care should be taken in patients with impaired kidney function as this medication may take longer to be excreted from the body, potentially causing problems. Patients taking the heart medication digoxin should be particularly careful as this medication may affect the heart. Gastrointestinal symptoms such as dyspepsia, diarrhea, constipation, nausea, vomiting, and abdominal pain may occur while taking this medication. Blood tests may show an increase in red blood cell count or a decrease in white blood cell count. Liver function test values may increase, so monitoring liver health through tests is necessary. Allergic reactions such as skin rashes may occur. High blood uric acid levels may cause gout symptoms to develop. Side effects related to the kidneys and urinary tract can include elevated kidney function test values, kidney stones, increased urine output, and urinary stones. Neurological symptoms such as headache, dizziness, fatigue, drowsiness, and insomnia have also been reported. Joint pain or, rarely, interstitial pneumonia with lung inflammation may also occur. This medication can elevate uric acid levels in the blood and urine, so it is advisable to regularly monitor uric acid levels and kidney function during treatment. There are no significant drug interactions with this medication; however, it should not be used in conjunction with corticosteroids, immunoglobulins, cytotoxic agents, or antithymocyte globulin. Safety has not been established during pregnancy; it is advisable not to use during the first three months of pregnancy, and use should be cautious only when necessary in pregnant women. This medication can be passed through breast milk, so it is advisable to stop breastfeeding during treatment. In cases of overdose, symptoms such as vomiting, headache, discomfort in the upper abdomen, dizziness, and palpitations may occur, but symptoms will resolve by reducing the dosage or discontinuing the medication. In cases of overdose, appropriate treatment should be received based on the symptoms.

Upper abdominal discomfort, diarrhea, constipation, gastrointestinal bleeding, nausea, vomiting, epigastric pain, increased red blood cells, decreased white blood cells, increased platelets, elevated AST/ALT, elevated γ-GTP, elevated ALP, elevated LDH, rash, hyperuricemia, elevated BUN, kidney stones accompanied by hypercalcemia, polyuria, urinary stones, headache, dizziness, fatigue, lethargy, nervousness, drowsiness, insomnia, joint pain, interstitial pneumonia, palpitations

This medication may be sensitive to air or moisture, so it should be stored in a sealed container. Additionally, avoid storing in extremely hot or cold places, and it is best to keep it at room temperature between 1 degrees Celsius and 30 degrees Celsius.

Appearance

Colorless to light brown syrup with a caramel flavor

Package unit

500 milliliters/bottle